Project description
A blood test for antidepressant medication choice
Treatment of major depressive disorder is based on a trial-and-error approach, with patients trying several different medications and often without the desired response. This has a huge socioeconomic impact affecting millions of people who struggle to recover. Funded by the European Innovation Council, the RxMine project introduces a novel platform to assist the search of the best antidepressant for each patient. The process involves the analysis of a patient blood sample to predict the individual response to various medications. It is based on a brain-in-a-dish model that allows high-throughput screening of available drugs and machine learning to identify the most effective choice in a fast and effortless way.
Fields of science
- natural sciencesbiological sciencesneurobiology
- natural sciencesbiological sciencesgenetics
- medical and health sciencesbasic medicinepharmacology and pharmacypharmaceutical drugs
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- engineering and technologymedical engineeringmedical laboratory technologylaboratory samples analysis
- natural sciencescomputer and information sciencesartificial intelligencemachine learning
Programme(s)
- HORIZON.3.1 - The European Innovation Council (EIC) Main Programme
Funding Scheme
HORIZON-AG - HORIZON Action Grant Budget-Based
Coordinator
6744332 Tel Aviv
Israel
See on map